ALNY PE Ratio & Valuation,Is ALNY Overvalued

ALNY Relative Valuation

ALNY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ALNY is overvalued; if below, it's undervalued.

Historical Valuation

Alnylam Pharmaceuticals Inc (ALNY) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -44.23. The fair price of Alnylam Pharmaceuticals Inc (ALNY) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 391.50 USD , Alnylam Pharmaceuticals Inc is Undervalued By Fair.

Relative Value

Fair Zone

+Inf-+Inf

Current Price：391.50

Fair

Undervalued

59.08

43.36

EV/EBITDA

Alnylam Pharmaceuticals Inc. (ALNY) has a current EV/EBITDA of 43.36. The 5-year average EV/EBITDA is -7426.85. The thresholds are as follows: Strongly Undervalued below -124449.02, Undervalued between -124449.02 and -65937.93, Fairly Valued between 51084.23 and -65937.93, Overvalued between 51084.23 and 109595.31, and Strongly Overvalued above 109595.31. The current Forward EV/EBITDA of 43.36 falls within the Historic Trend Line -Fairly Valued range.

44.81

EV/EBIT

Alnylam Pharmaceuticals Inc. (ALNY) has a current EV/EBIT of 44.81. The 5-year average EV/EBIT is -75.23. The thresholds are as follows: Strongly Undervalued below -1578.72, Undervalued between -1578.72 and -826.97, Fairly Valued between 676.51 and -826.97, Overvalued between 676.51 and 1428.26, and Strongly Overvalued above 1428.26. The current Forward EV/EBIT of 44.81 falls within the Historic Trend Line -Fairly Valued range.

10.14

Alnylam Pharmaceuticals Inc. (ALNY) has a current PS of 10.14. The 5-year average PS is 15.49. The thresholds are as follows: Strongly Undervalued below 7.51, Undervalued between 7.51 and 11.50, Fairly Valued between 19.48 and 11.50, Overvalued between 19.48 and 23.47, and Strongly Overvalued above 23.47. The current Forward PS of 10.14 falls within the Undervalued range.

28.82

P/OCF

Alnylam Pharmaceuticals Inc. (ALNY) has a current P/OCF of 28.82. The 5-year average P/OCF is 103.45. The thresholds are as follows: Strongly Undervalued below -586.57, Undervalued between -586.57 and -241.56, Fairly Valued between 448.46 and -241.56, Overvalued between 448.46 and 793.47, and Strongly Overvalued above 793.47. The current Forward P/OCF of 28.82 falls within the Historic Trend Line -Fairly Valued range.

45.58

P/FCF

Alnylam Pharmaceuticals Inc. (ALNY) has a current P/FCF of 45.58. The 5-year average P/FCF is -71.21. The thresholds are as follows: Strongly Undervalued below -1773.17, Undervalued between -1773.17 and -922.19, Fairly Valued between 779.77 and -922.19, Overvalued between 779.77 and 1630.75, and Strongly Overvalued above 1630.75. The current Forward P/FCF of 45.58 falls within the Historic Trend Line -Fairly Valued range.

Alnylam Pharmaceuticals Inc (ALNY) has a current Price-to-Book (P/B) ratio of 220.50. Compared to its 3-year average P/B ratio of -1078.18 , the current P/B ratio is approximately -120.45% higher. Relative to its 5-year average P/B ratio of -643.57, the current P/B ratio is about -134.26% higher. Alnylam Pharmaceuticals Inc (ALNY) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -0.47%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -1.68% , the current FCF yield is about -100.00% lower.

220.50

P/B

Median3y

-1078.18

Median5y

-643.57

0.42

FCF Yield

Median3y

-0.47

Median5y

-1.68

Competitors Valuation Multiple

The average P/S ratio for ALNY's competitors is 2.49, providing a benchmark for relative valuation. Alnylam Pharmaceuticals Inc Corp (ALNY) exhibits a P/S ratio of , which is -100% above the industry average. Given its robust revenue growth of 149.35%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of ALNY increased by 66.38% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 500.92M to 1.25B.

The secondary factor is the P/E Change, contributed 107.29%to the performance.

Overall, the performance of ALNY in the past 1 year is driven by Revenue Growth. Which is more sustainable.

149.35%

500.92M → 1.25B

Revenue Growth

-190.26%

-22.27 → 20.10

Margin Expansion

107.29%

572.31 → 1.19K

P/E Change

66.38%

235.31 → 391.50

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Alnylam Pharmaceuticals Inc (ALNY) currently overvalued or undervalued?

What is Alnylam Pharmaceuticals Inc (ALNY) fair value?

ALNY's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Alnylam Pharmaceuticals Inc (ALNY) is between +Inf to +Inf according to relative valuation methord.

How does ALNY's valuation metrics compare to the industry average?

The average P/S ratio for ALNY's competitors is 2.49, providing a benchmark for relative valuation. Alnylam Pharmaceuticals Inc Corp (ALNY) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 149.35%, this premium appears sustainable.

What is the current P/B ratio for Alnylam Pharmaceuticals Inc (ALNY) as of Dec 16 2025?

As of Dec 16 2025, Alnylam Pharmaceuticals Inc (ALNY) has a P/B ratio of 220.50. This indicates that the market values ALNY at 220.50 times its book value.

What is the current FCF Yield for Alnylam Pharmaceuticals Inc (ALNY) as of Dec 16 2025?

As of Dec 16 2025, Alnylam Pharmaceuticals Inc (ALNY) has a FCF Yield of 0.00%. This means that for every dollar of Alnylam Pharmaceuticals Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Alnylam Pharmaceuticals Inc (ALNY) as of Dec 16 2025?

As of Dec 16 2025, Alnylam Pharmaceuticals Inc (ALNY) has a Forward P/E ratio of 59.08. This means the market is willing to pay $59.08 for every dollar of Alnylam Pharmaceuticals Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Alnylam Pharmaceuticals Inc (ALNY) as of Dec 16 2025?

As of Dec 16 2025, Alnylam Pharmaceuticals Inc (ALNY) has a Forward P/S ratio of 0.00. This means the market is valuing ALNY at $0.00 for every dollar of expected revenue over the next 12 months.

ALNY Valuation